Private company

IMV Inc.

IMV Inc. is a pharmaceutical preparations company based in Dartmouth.¹

Last updated Oct 21, 2026.

Overview

IndustryPharmaceutical Preparations¹
HeadquartersDartmouth, Canada¹
Incorporated inCanada (Federal Level)²
Business address130 Eileen Stubbs Ave., Suite 19, Dartmouth, A5 B3B 2C4²
Filer categoryNon-accelerated filer, Emerging growth company²
Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-19462.2%Net margin³

-16.4%Revenue growth, 2021⁴

-169.8%Return on equity³

0.83×Debt to equity³

-$34.6MFree cash flow³

Where the money goes

Where each dollar of revenue went, fiscal 2021

Research and development

Research and development100¢$23.1M
Interest0¢$239

Out of $188.0K in revenue.⁴³ The company lost money this year.

Financial statements

Revenue⁴$188.0K in 2021−16% since 2020

Net income³-$36.6M in 2021+40% since 2020

Fiscal year	2020	2021
Revenue	$225.0K⁴	$188.0K⁴
Research and development		$23.1M³
Interest		$239³
Income before tax		-$36.6M³
Net income	-$26.1M³	-$36.6M³
Earnings per share	-$3.88³	-$4.93³
Earnings per share (diluted)	-$3.88³	-$4.93³
Shares (weighted, basic)		7.4M shares³
Shares (weighted, diluted)		7.4M shares³

Total assets⁴³$50.1M in 2021+9% since 2020

Total liabilities⁴³$28.6M in 2021+88% since 2020

Shareholders’ equity³$21.5M in 2021+335% since 2019

Cash³$38.6M in 2021+257% since 2019

Fiscal year	2018	2019	2020	2021
Cash		$10.8M³	$36.3M³	$38.6M³
Receivables				$602.0K⁴
Current assets				$46.4M³
Property, plant and equipment				$3.7M³
Total assets			$46.0M⁴	$50.1M³
Accounts payable				$8.6M³
Short-term debt				$73.0K³
Current liabilities				$9.3M³
Long-term debt				$17.9M³
Total liabilities			$15.2M⁴	$28.6M³
Retained earnings				-$154.9M⁴
Shareholders’ equity		$5.0M³	$30.8M³	$21.5M³
Shares outstanding	45.1M shares⁵	51.0M shares⁶	67.1M shares⁷	82.2M shares⁴

Cash from operations³-$33.2M in 2021+49% since 2020

Capital spending³$1.4M in 2021+324% since 2020

Free cash flow³-$34.6M in 2021+53% since 2020

Fiscal year	2020	2021
Cash from operations	-$22.3M³	-$33.2M³
Capital spending	$331.0K³	$1.4M³
Free cash flow	-$22.6M	-$34.6M
Cash from financing		$35.8M³

Compare IMV Inc. with another company

Corporate structure

IMV Inc. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of IMV Inc.

ARMISTICE CAPITAL, LLC Filed SC 13G on IMV Inc., latest Feb 14, 2023
Fonds de solidarite des travailleurs et des travailleuses du Quebec Filed SC 13G/A on IMV Inc., latest Feb 3, 2023

IMV Inc. Dartmouth, Canada

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What IMV Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Property and equipment, net	$3.8M³ Dec 31, 2022	$3.7M³ Dec 31, 2021	+0.8%
Operating-lease assets (leased space)	$108.0K³ Dec 31, 2022	$719.0K³ Dec 31, 2021	−85.0%

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	$21.2M³ Dec 31, 2022	$38.6M³ Dec 31, 2021	−45.0%

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

Executive OfficerAndrew Hall named Jan 3, 2022⁸
Executive OfficerJeremy Graff named Jan 3, 2022⁸
Executive OfficerPierre Labbe named Jan 3, 2022⁸
DirectorAndrew Sheldon named Jan 3, 2022⁸
DirectorJulia Gregory named Jan 3, 2022⁸
DirectorKyle Kuvalanka named Jan 3, 2022⁸
DirectorMarkus Warmuth named Jan 3, 2022⁸
DirectorMichael Bailey named Jan 3, 2022⁸
DirectorMichael Kalos named Jan 3, 2022⁸
DirectorShermaine Tilley named Jan 3, 2022⁸

Former names

Immunovaccine Inc.May 1, 2018 to May 1, 2018²

Filings

89 filings to the SEC since October 2021: 2 annual reports, 2 large holders, 1 private raises, 84 other. The latest 20:

Sep 22, 202315-12G EDGAR
Sep 22, 2023F-10POS EDGAR
Sep 22, 2023F-10POS EDGAR
Sep 22, 2023F-10POS EDGAR
Sep 22, 2023S-8 POS EDGAR
Sep 22, 2023S-8 POS EDGAR
Sep 22, 2023S-8 POS EDGAR
Sep 22, 2023S-8 POS EDGAR
Sep 22, 2023S-8 POS EDGAR
Jul 26, 20236-K REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JULY, 2023 EDGAR
May 8, 20236-K REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MARCH, 2023 EDGAR
Mar 31, 20236-K REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MARCH, 2023 EDGAR
Mar 28, 20236-K REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MARCH, 2023 EDGAR
Mar 16, 20236-K REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MARCH, 2023 EDGAR
Mar 16, 202320-F ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF EDGAR
Mar 9, 20236-K REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MARCH, 2023 EDGAR
Feb 14, 2023SC 13G EDGAR
Feb 13, 20236-K REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF FEBRUARY, 2023 EDGAR
Feb 3, 2023SC 13G/A AMENDMENT NO. 2 EDGAR
Jan 9, 20236-K REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JANUARY, 2023 EDGAR

The 89 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

ARMISTICE CAPITAL, LLCSC 13G, 1 filing Feb 14, 2023⁹
Fonds de solidarite des travailleurs et des travailleuses du QuebecSC 13G/A, 1 filing Feb 3, 2023¹⁰

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

Dec 17, 2021Filed a private offering of equity⁸ Form D: $749,998 offered in all Form D

SEC filer profile

How IMV Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARIMV Inc.¹
CIK0001734768
Filer statusNon-accelerated filer<br>emerging growth company¹
Incorporated inCanada (Federal Level)¹
Fiscal year endsDecember 31¹
Industry code (SIC)2834 Pharmaceutical Preparations¹
Business address130 Eileen Stubbs Ave., Suite 19, Dartmouth, A5 B3B 2C4¹
Phone9024921819¹
Shares outstanding11,711,637 as of Mar 15, 2023³
On EDGAR sinceMay 1, 2018¹
Filings293 in all: 6-K (225), SUPPL (12), S-8 POS (6), F-X (5), S-8 (5), 40-F (4), F-10 (4), SC 13G (4)¹
All 25 form types
EFFECT (3), F-10/A (3), F-10POS (3), SC 13G/A (3), D (2), F-X/A (2), UPLOAD (2), 15-12G (1), 20-F (1), 25-NSE (1), 40-F/A (1), 40FR12B (1), 40FR12B/A (1), CERT (1), CORRESP (1), POS AM (1), SC 13D (1)
Latest filingsAnnual report (20-F) Mar 16, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARIMV Inc. filings on SEC EDGAR
2
SEC EDGARIMV Inc. filings on SEC EDGAR
3
SEC EDGARIMV Inc. 10-K for fiscal 2021
4
SEC EDGARIMV Inc. 10-K for fiscal 2021
5
SEC EDGARIMV Inc. 10-K for fiscal 2018
6
SEC EDGARIMV Inc. 10-K for fiscal 2019
7
SEC EDGARIMV Inc. 10-K for fiscal 2020
8
SEC EDGARIMV Inc. Form D naming Andrew Hall
9
SEC EDGARARMISTICE CAPITAL, LLC SC 13G on IMV Inc.
10
SEC EDGARFonds de solidarite des travailleurs et des travailleuses du Quebec SC 13G/A on IMV Inc.